Unknown

Dataset Information

0

Dichloroacetate improves mitochondrial function, physiology, and morphology in FBXL4 disease models.


ABSTRACT: Pathogenic variants in the human F-box and leucine-rich repeat protein 4 (FBXL4) gene result in an autosomal recessive, multisystemic, mitochondrial disorder involving variable mitochondrial depletion and respiratory chain complex deficiencies with lactic acidemia. As no FDA-approved effective therapies for this disease exist, we sought to characterize translational C. elegans and zebrafish animal models, as well as human fibroblasts, to study FBXL4-/- disease mechanisms and identify preclinical therapeutic leads. Developmental delay, impaired fecundity and neurologic and/or muscular activity, mitochondrial dysfunction, and altered lactate metabolism were identified in fbxl-1(ok3741) C. elegans. Detailed studies of a PDHc activator, dichloroacetate (DCA), in fbxl-1(ok3741) C. elegans demonstrated its beneficial effects on fecundity, neuromotor activity, and mitochondrial function. Validation studies were performed in fbxl4sa12470 zebrafish larvae and in FBXL4-/- human fibroblasts; they showed DCA efficacy in preventing brain death, impairment of neurologic and/or muscular function, mitochondrial biochemical dysfunction, and stress-induced morphologic and ultrastructural mitochondrial defects. These data demonstrate that fbxl-1(ok3741) C. elegans and fbxl4sa12470 zebrafish provide robust translational models to study mechanisms and identify preclinical therapeutic candidates for FBXL4-/- disease. Furthermore, DCA is a lead therapeutic candidate with therapeutic benefit on diverse aspects of survival, neurologic and/or muscular function, and mitochondrial physiology that warrants rigorous clinical trial study in humans with FBXL4-/- disease.

SUBMITTER: Lavorato M 

PROVIDER: S-EPMC9462489 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dichloroacetate improves mitochondrial function, physiology, and morphology in FBXL4 disease models.

Lavorato Manuela M   Nakamaru-Ogiso Eiko E   Mathew Neal D ND   Herman Elizabeth E   Shah Nina N   Haroon Suraiya S   Xiao Rui R   Seiler Christoph C   Falk Marni J MJ  

JCI insight 20220822 16


Pathogenic variants in the human F-box and leucine-rich repeat protein 4 (FBXL4) gene result in an autosomal recessive, multisystemic, mitochondrial disorder involving variable mitochondrial depletion and respiratory chain complex deficiencies with lactic acidemia. As no FDA-approved effective therapies for this disease exist, we sought to characterize translational C. elegans and zebrafish animal models, as well as human fibroblasts, to study FBXL4-/- disease mechanisms and identify preclinical  ...[more]

Similar Datasets

| S-EPMC5453974 | biostudies-literature
| S-EPMC7338799 | biostudies-literature
| S-EPMC8482967 | biostudies-literature
| S-EPMC9968062 | biostudies-literature
| S-EPMC6562462 | biostudies-literature
| S-EPMC3769923 | biostudies-literature
2016-12-02 | PXD005138 | Pride
| S-EPMC3769921 | biostudies-literature
| S-EPMC8452856 | biostudies-literature
| S-EPMC6964686 | biostudies-literature